Sterling Capital Management LLC Has $4.15 Million Holdings in West Pharmaceutical Services, Inc. $WST

Sterling Capital Management LLC trimmed its holdings in West Pharmaceutical Services, Inc. (NYSE:WST) by 10.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 16,564 shares of the medical instruments supplier’s stock after selling 1,984 shares during the quarter. Sterling Capital Management LLC’s holdings in West Pharmaceutical Services were worth $4,152,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Elyxium Wealth LLC acquired a new position in West Pharmaceutical Services during the 4th quarter valued at $25,000. CYBER HORNET ETFs LLC acquired a new stake in West Pharmaceutical Services in the 2nd quarter worth $25,000. Bayban acquired a new stake in West Pharmaceutical Services in the 4th quarter worth $27,000. Private Trust Co. NA increased its holdings in shares of West Pharmaceutical Services by 156.4% during the 4th quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier’s stock worth $28,000 after purchasing an additional 61 shares during the period. Finally, DV Equities LLC bought a new position in shares of West Pharmaceutical Services during the 4th quarter worth about $28,000. Institutional investors own 93.90% of the company’s stock.

Insider Buying and Selling

In other news, VP Annette F. Favorite sold 2,817 shares of the stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $305.20, for a total value of $859,748.40. Following the completion of the transaction, the vice president directly owned 16,828 shares of the company’s stock, valued at approximately $5,135,905.60. This represents a 14.34% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CAO Chad Winters sold 896 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $300.67, for a total value of $269,400.32. Following the transaction, the chief accounting officer owned 1,523 shares of the company’s stock, valued at $457,920.41. This trade represents a 37.04% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 0.60% of the company’s stock.

West Pharmaceutical Services Stock Performance

NYSE WST opened at $351.07 on Friday. West Pharmaceutical Services, Inc. has a twelve month low of $206.80 and a twelve month high of $352.31. The company has a quick ratio of 2.04, a current ratio of 2.71 and a debt-to-equity ratio of 0.07. The stock has a market cap of $24.80 billion, a P/E ratio of 46.93, a PEG ratio of 2.94 and a beta of 1.18. The company’s 50-day simple moving average is $313.84 and its 200 day simple moving average is $275.59.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 EPS for the quarter, topping analysts’ consensus estimates of $1.68 by $0.45. The firm had revenue of $844.90 million during the quarter, compared to analysts’ expectations of $779.67 million. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The company’s revenue for the quarter was up 21.0% compared to the same quarter last year. During the same quarter last year, the company earned $1.45 earnings per share. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. As a group, research analysts forecast that West Pharmaceutical Services, Inc. will post 8.6 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Barclays upgraded shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $310.00 to $400.00 in a research note on Tuesday, June 9th. Wolfe Research started coverage on West Pharmaceutical Services in a research note on Monday, June 1st. They set an “outperform” rating and a $375.00 price target on the stock. Weiss Ratings raised West Pharmaceutical Services from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, April 27th. Citigroup reiterated a “buy” rating on shares of West Pharmaceutical Services in a research report on Friday, April 24th. Finally, Evercore reissued an “outperform” rating on shares of West Pharmaceutical Services in a report on Friday, April 24th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $340.09.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.